Publication

A benzenesulfonamide derivative as a novel PET radioligand for CXCR4

Downloadable Content

Persistent URL
Last modified
  • 05/22/2025
Type of Material
Authors
    Yoon Hyeun Oum, Emory UniversityDinesh Shetty, Emory UniversityYounghyoun Yoon, Emory UniversityZhongxing Liang, Emory UniversityRonald Voll, Emory UniversityMark Goodman, Emory UniversityHyunsuk Shim, Emory University
Language
  • English
Date
  • 2020-01-15
Publisher
  • PERGAMON-ELSEVIER SCIENCE LTD
Publication Version
Copyright Statement
  • 2019
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 28
Issue
  • 2
Start Page
  • 115240
End Page
  • 115240
Supplemental Material (URL)
Abstract
  • CXCR4 is involved in various diseases such as inflammation, tumor growth, and cancer metastasis through the interaction with its natural endogenous ligand, chemokine CXCL12. In an effort to develop imaging probes for CXCR4, we developed a novel small molecule CXCR4-targeted PET agent (compound 5) by combining our established benzenesulfonamide scaffold with a labeling component by virtue of click chemistry. 5 shows nanomolar affinity (IC50 = 6.9 nM) against a known CXCR4 antagonist (TN14003) and inhibits more than 65% chemotaxis at 10 nM in vitro assays. Radiofluorinated compound 5 ([18F]5) demonstrates a competitive cellular uptake against CXCL12 in a dose-dependent manner. Further, microPET images of [18F]5 exhibits preferential accumulation of radioactivity in the lesions of λ-carrageenan-induced paw edema, human head and neck cancer orthotopic xenograft, and metastatic lung cancer of each mouse model.
Author Notes
  • Department of Radiation Oncology, Emory University School of Medicine. 1365 Clifton Road NE, Building C., Atlanta GA, 30322, USA.
Keywords
Research Categories
  • Biology, Molecular
  • Chemistry, Biochemistry
  • Chemistry, Organic

Tools

Relations

In Collection:

Items